10-K/A: Pulmatrix Amends 10-K, Awaits Cullgen Merger Approval

Pulmatrix, Inc. filed an amended annual report to correct a typographical error and provided updated financial statements showing reduced operating expenses and net loss, while awaiting critical regulatory approval for its merger with Cullgen Inc.

Summary

• The filing is an Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, primarily to correct a typographical error in the date of the Report of Independent Registered Public Accounting Firm and to include updated certifications.
• Pulmatrix's future operations are highly dependent on the successful consummation of its merger with Cullgen Inc., which is still awaiting approval from the China Securities Regulatory Commission (CSRC).
• Pre-Merger Cullgen stockholders are expected to own approximately 96.4% of the combined company, with pre-Merger Pulmatrix stockholders owning approximately 3.6% on a fully-diluted basis.
• The company reported a net loss of $(5,162) thousand for the year ended December 31, 2025, an improvement from $(9,559) thousand in 2024.
• Cash and cash equivalents decreased significantly to $4,088 thousand as of December 31, 2025, from $9,521 thousand in 2024.
• Research and development expenses were drastically reduced to $38 thousand in 2025 from $7,166 thousand in 2024, following the wind-down of the Cipla agreement and the MannKind transaction.
• All performance obligations under the Cipla Agreement were satisfied as of December 31, 2025, and no revenue was recognized from this agreement in 2025, compared to $6,900 thousand in 2024.
• The company completed the MannKind Transaction in July 2024, which involved assigning its former lease, transferring intellectual property, and MannKind hiring a majority of Pulmatrix's R&D staff.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development, reflecting a company in a distressed state, relying on a reverse merger for survival, with significant shareholder dilution and explicit risks of dissolution if the merger fails.

Positives

• Net loss improved to $(5,162) thousand in 2025 from $(9,559) thousand in 2024.
• Net cash used in operating activities significantly decreased to $(5,433) thousand in 2025 from $(10,716) thousand in 2024, indicating reduced cash burn.
• All performance obligations under the Cipla Agreement were satisfied as of December 31, 2025, concluding a significant collaboration.
• The company's stockholders approved the merger with Cullgen Inc. and related proposals on June 16, 2025.
• Management believes current cash and cash equivalents are adequate to fund operating expenses for at least twelve months if the merger is not consummated.

Negatives

• No revenue was recognized in 2025, a significant drop from $7,806 thousand in 2024.
• Cash and cash equivalents decreased by over 50% from $9,521 thousand in 2024 to $4,088 thousand in 2025.
• Total assets decreased significantly from $9,943 thousand in 2024 to $4,139 thousand in 2025.
• The company's future operations are highly dependent on the success of the merger with Cullgen, which faces regulatory hurdles.
• If the merger is not consummated, the company would need substantial additional funding for program development, which may not be available on acceptable terms.
• The board of directors may decide to pursue a dissolution and liquidation if the strategic review process and merger are unsuccessful.

Risks

• The successful consummation of the merger with Cullgen Inc. is not assured and is subject to customary closing conditions, including regulatory approvals from Nasdaq and the China Securities Regulatory Commission (CSRC).
• There is no assurance that the strategic review process or any transaction relating to a specific asset, including the merger and any asset sale, will result in the company pursuing such a transaction, or that any transactions, if pursued, will be completed on terms favorable to Pulmatrix and its stockholders.
• If the strategic review process is unsuccessful, and if the merger is not consummated, the company's board of directors may decide to pursue a dissolution and liquidation in the future.
• If the merger is not consummated, the company would need to secure substantial additional funding in the future to continue development of its programs, and such funding may not be available on acceptable terms, or at all.
• The company's ongoing research and development activities are subject to extensive regulation by numerous governmental authorities, including the FDA, and there is no assurance that problems will not be encountered in clinical trials that could delay or suspend them.
• The company's success in developing product candidates depends on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the property rights of others, with no assurance that patents will not be challenged, invalidated, or circumvented.
• The company is exposed to credit risk for cash and cash equivalents deposited in accounts at a single financial institution for amounts in excess of Federal Deposit Insurance Corporation (FDIC) insured limits.

Future Outlook

Pulmatrix's future operations are highly dependent on the success of the merger with Cullgen Inc. If the merger is completed, Cullgen's business will continue as the business of the combined company, and Pulmatrix will seek to monetize its intellectual property, including iSPERSE and its clinical assets. If the merger is not consummated, the company believes its current cash and cash equivalents would be adequate to fund operating expenses for at least twelve months, but substantial additional funding would be required for program development, which may not be available. The board may consider dissolution and liquidation if the strategic review and merger are unsuccessful.

Management Comments

• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
• "Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Pulmatrix's strategy to merge with Cullgen, a company with a significantly higher valuation, reflects a common trend among smaller biotechs to seek strategic combinations to gain scale, access new pipelines, or secure funding. The substantial reduction in Pulmatrix's R&D expenses and the cessation of revenue generation from its Cipla agreement indicate a pivot away from its previous operational model, likely in preparation for the merger and the monetization of its existing IP. The reliance on a single, large transaction (the Cullgen merger) for future viability highlights the inherent risks in this sector, particularly for companies with limited cash reserves and no current revenue streams.

Comparison to Industry Standards

• Pulmatrix's current financial state, with no revenue in 2025 and a significant cash burn, is below industry standards for a publicly traded biopharmaceutical company actively developing products. For example, larger, more established biotechs like Amgen or Gilead Sciences generate billions in revenue and maintain robust R&D pipelines.
• The proposed merger with Cullgen, where Pulmatrix shareholders would own only 3.6% of the combined entity, suggests a 'reverse merger' scenario, often indicative of a company seeking to leverage its public listing for a private entity with more promising assets. This is a common strategy for struggling public companies but typically results in significant dilution for existing shareholders.
• The valuation of Pulmatrix at $10.5 million compared to Cullgen's $280.0 million for the merger underscores the relative size and perceived value of the two entities, with Pulmatrix contributing primarily its public listing and remaining cash. This contrasts sharply with mergers of equals or acquisitions where the target company commands a premium.
• The complete cessation of revenue from the Cipla agreement and the drastic reduction in R&D spending to $38 thousand in 2025 are highly unusual for a biopharmaceutical company, signaling a near-complete halt of internal drug development activities, unlike peers such as Vertex Pharmaceuticals or BioNTech which continuously invest heavily in R&D.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Significant dilution expected if the merger with Cullgen is completed (Pulmatrix stockholders to own ~3.6% of combined company). Potential cash dividend if net cash exceeds $2.5 million. Risk of dissolution and liquidation if the merger fails.
• Employees: Majority of research and development employees (approximately two-thirds of the workforce) were terminated by Pulmatrix and hired by MannKind in July 2024.
• Customers/Partners: All performance obligations under the Cipla Agreement have been satisfied, indicating the conclusion of that collaboration. MannKind Corporation is now a key partner through the Intellectual Property Cross License Agreement and Master Services Agreement.
• Creditors: The company's liquidity position has deteriorated, but management believes current cash is sufficient for 12 months if the merger fails. The risk of dissolution could impact creditors.

Next Steps

• Obtain approval from the China Securities Regulatory Commission (CSRC) for the merger with Cullgen Inc.
• Complete the merger with Cullgen Inc.
• Declare a cash dividend to pre-Merger Pulmatrix stockholders if net cash exceeds $2.5 million prior to the closing of the merger.
• Seek to monetize intellectual property, including iSPERSE and clinical assets, concurrent with the merger.
• If the merger is not consummated, secure substantial additional funding for program development or potentially pursue dissolution and liquidation.
• Evaluate the impact of ASU 2024-03 (Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures) for adoption in annual periods beginning after December 15, 2026.

Key Dates

Recommendation

The company's current financial state is dire, with no revenue, rapidly depleting cash, and a high dependency on a merger that would result in extreme dilution for existing shareholders (3.6% ownership). The explicit risk of dissolution and liquidation if the merger fails presents an existential threat. While the net loss improved, it was due to a cessation of operational activities rather than a return to profitability. The prolonged regulatory approval process for the merger adds further uncertainty. Investors face substantial downside risk with minimal upside potential in the current Pulmatrix entity.

Keywords

Pulmatrix, Cullgen, Merger, Biopharmaceutical, iSPERSE, SEC filing, 10-K/A, Financials, Net Loss, Cash Flow, R&D, Cipla, MannKind, Regulatory Approval, CSRC, Liquidity, Dissolution Risk, Stockholders Equity, Warrants, Stock-based Compensation